Thomas Proft

Has grant

Professor

University of Auckland
Country flag
New Zealand

Research Interests

Explore related searches

Contact this professor

LinkedIn
ORCID
Google Scholar

About

Professor Thomas Proft is a faculty member at The University of Auckland in New Zealand. His research focuses on the pathogenesis of Group A Streptococcus, including its virulence factors and implications for vaccine development. Recent publications highlight his work on the immune evasion strategies of pathogenic Gram-positive bacteria and novel mechanisms to enhance oral drug delivery through PEGylated niosomes.

Recent Grants

Grant: Close

Investigations into a novel putative immune evasion factor from Group A Streptococcus

Open Date: 2018-11-01

Close Date: 2020-11-01

Grant: Close

GASPEL - a novel mucosal vaccine against Group A Streptococcus?

Open Date: 2018-10-01

Close Date: 2020-09-01

Grant: Close

PilVax a novel peptide delivery strategy for the development of vaccines against TB

Open Date: 2017-03-01

Close Date: 2020-02-01

Grant: Close

PilVax: a novel peptide delivery strategy for the development of vaccines

Open Date: 2017-01-01

Close Date: 2020-01-01

Grant: Close

Can vaccination with PilVax stimulate protective immunity to Staphylococcus aureus?

Open Date: 2016-08-01

Close Date: 2018-07-01

Articles (15)

Different Group A Streptococcus pili lead to varying proinflammatory cytokine responses and virulence

The human pathogen Streptococcus pyogenes , or Group A Streptococcus (GAS), is associated with a variety of diseases ranging from mild skin and soft tissue infections to invasive diseases and immune sequelae such as rheumatic heart disease. We have recently reported that one of the virulence factors of this pathogen, the pilus, has inflammatory properties and strongly stimulates the innate immune system. Here we used a range of nonpathogenic Lactococcus lactis gain‐of‐function mutants, each expressing one of the major pilus types of GAS, to compare the immune responses generated by various types of fully assembled pili. In vitro assays indicated variability in the inflammatory response induced by different pili, with the fibronectin‐binding, collagen‐binding, T antigen (FCT)‐1‐type pilus from GAS serotype M6/T6 inducing significantly stronger cytokine secretion than other pili. Furthermore, we established that the same trend of pili‐mediated immune response could be modeled in Galleria mellonella larvae, which possess a similar innate immune system to vertebrates. Counterintuitively, across the panel of pili types examined in this study, we observed a negative correlation between the intensity of the immune response demonstrated in our experiments and the disease severity observed clinically in the GAS strains associated with each pilus type. This observation suggests that pili‐mediated inflammation is more likely to promote bacterial clearance instead of causing disruptive damages that intensify pathogenesis. This also indicates that pili may not be the main contributor to the inflammatory symptoms seen in GAS diseases. Rather, the immune‐potentiating properties of the pilus components could potentially be exploited as a vaccine adjuvant.

Year:

2023

Collaborators (8)

Joanna Kirman

Associate Professor

University of Otago

NEW ZEALAND

Jacelyn Mei San Loh

-

NEW ZEALAND

Yi Tian Ting

MONASH UNIVERSITY

AUSTRALIA

Adrina Hema Jethanand-Khemlani

University of Auckland

NEW ZEALAND

Darren Svirskis

University of Auckland

NEW ZEALAND

Catherine Jia‐Yun Tsai

-

NEW ZEALAND

Mengyang Liu

University of Auckland

NEW ZEALAND

Jingyuan Wen

Associate Professor

University of Auckland

NEW ZEALAND
Social connections

How do I reach out?

Sign in for free to see their profile details and contact information.

Meet Kite AI